Clinical Guidelines
Feature

Targeted NGS Streamlines Myeloproliferative Neoplasm Diagnostics

Kritika Krishnamurthy shares real-world experience on advanced MPN genomic profiling

  • March 18, 2026

  • 9 min

Share

The evolving diagnostic landscape of myeloproliferative neoplasms (MPNs) emphasizes comprehensive molecular characterization using next-generation sequencing (NGS) and high-sensitivity PCR. Dr. Kritika Krishnamurthy highlighted integrating NGS with PCR, presenting case studies demonstrating the limitations of traditional sequential PCR and the advantages of NGS in identifying co-mutations and low-level variants, contributing to better prognostic information and therapy guidance. NCCN guidelines now favor NGS use in MPN diagnostics to improve patient care.

Original Source(s)

Targeted NGS Streamlines Myeloproliferative Neoplasm Diagnostics

  • March 18, 2026

Related Content

Romiplostim May Improve Chemotherapy-Induced Thrombocytopenia in Patients With GI Cancers

Romiplostim was beneficial in treating chemotherapy-induced thrombocytopenia, according to findings from the global phase III RECITE trial published in The New England Journal of Medicine.  

Register Today for Roswell Park’s Upstate New York Hematology & Hematologic Oncology Conference

Register for the Upstate New York Hematology & Hematologic Oncology Conference: A Review of the 67th ASH Annual meeting, taking place on April 25-26 in Buffalo, NY.

  • by

  • March 13, 2026

  • 1 min
Enhancing Immune Thrombocytopenia Education and Support: Insights From a Learning Exchange Program